Clinical trials: Beta-cell Function
Type1 Diabetes Mellitus
BOL-DP-o-05 as an Add-On Treatment of Subjects With Newly Diagnosed Type 1 Diabetes Mellitus
BOL-DP-o-05 as an Add-On Treatment for Preservation of Beta-Cell Function in Subjects With Newly-Diagnosed Type 1 Diabetes Mellitus (T1DM)
- Trial name
- NCT04102202
- Testing
- BOL-DP-o-05
- Sponsor
- Breath of Life International Pharma Ltd
Diabetes Mellitus
Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy
Type I diabetes (T1DM) is the second most common chronic illness effecting children in the USA. Worldwide, Type I diabetes is increasing in incidence, and its underlying etiology remains elusive.
- Trial name
- ktpump (NCT00574405)
- Testing
- MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®]), CSII (Animas Corporation insulin pump, model IR 1200)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Arkansas Children's Hospital Research Institute
Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1
Baby Detect : Genomic Newborn Screening
Newborn screening (NBS) is a global initiative of systematic testing at birth to identify babies with pre-defined severe but treatable conditions.
- Conditions
- Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1, Phosphoglucomutase 1 Deficiency, Maturity Onset Diabetes of the Young
- Trial name
- BabyDetect (NCT05687474)
- Where
- Belgium
- Volunteers
- 6,824 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Liege
Diabetes Mellitus Type 1, Autoimmune Diabetes
Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes
Background: Type 1 diabetes (T1D) occurs when the immune system attacks insulin-producing cells (beta cells) in the pancreas, resulting in their death.
- Trial name
- NCT00837759
- Testing
- Insulin, Lansoprazole, Sitagliptin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 1 Diabetes
Closed Loop From Onset in Type 1 Diabetes
The purpose of the study is to use a novel treatment approach, the artificial pancreas, after diagnosis of type 1 diabetes (T1D) to improve glucose control with the anticipated improvements of residual C-peptide secretion.
- Trial name
- CLOuD (NCT02871089)
- Testing
- Closed-loop system (Florence M or CamAPS FX), Multiple Daily Injections
- Where
- 7 sites in United Kingdom
- Volunteers
- 96 people
- Sponsor
- University of Cambridge
Diabetes Mellitus, Insulin-Dependent
Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)
Within 4 weeks after diagnosis of type 1 diabetes, 10 subjects (pubertal males, 12-17 years old) will be randomized to either receive multiple daily injection (MDI) using Lantus insulin, or continuous subcutaneous insulin…
- Trial name
- NCT00357890
- Testing
- Insulin pump therapy, Multiple daily injections using insulin glargine + rapid acting analog
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Nemours Children's Clinic
Islets of Langerhans Transplantation, Pancreatitis, Chronic
Clinical Outcome After Total Pancreatectomy With Islet Autotransplantation
A total pancreatectomy with islet autotransplantation (TPIAT) can be performed for a number of benign indications, such as chronic pancreatitis.
- Conditions
- Islets of Langerhans Transplantation, Pancreatitis, Chronic, Diabetes Mellitus
- Trial name
- TOPPER (NCT05287737)
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Leiden University Medical Center
Cystic Fibrosis Related Diabetes, Cystic Fibrosis (CF)
Verapamil Effect in Cystic Fibrosis-related Dysglycemia
The investigators are conducting a pilot open-label pre/post interventional trial in adolescents and adults with cystic fibrosis (CF) and abnormal glucose tolerance or early CF-related diabetes mellitus (CFRD) to assess the…
- Conditions
- Cystic Fibrosis Related Diabetes, Cystic Fibrosis (CF), Abnormal Glucose Tolerance
- Trial name
- NCT07688070
- Testing
- Verapamil Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Rhode Island Hospital
Type 1 Diabetes
Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes
This project is designed to study the role of vitamin D supplementation on the honeymoon phase of type 1 diabetes in children who are on standardized insulin treatment.
- Trial name
- PCR (NCT03046927)
- Testing
- Ergocalciferol
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Benjamin U. Nwosu, MD
Heart Rate Variability (ANS Function)
Autonomic Nervous System and Sickle Cell Disease
Sickle cell disease (SCD) children and adults with asthma have an increased rate of vaso-occlusive crisis, acute chest syndrome episodes, and premature mortality when compared to those without asthma.
- Trial name
- DrepaSympa (NCT04062409)
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Type 2 Diabetes Mellitus (T2DM), Beta Cell Function
Function of Beta Cells in Early-onset Diabetes Mellitus
Research objectives: Evaluate and compare the clinical and paraclinical characteristics, complications, as well as the changes in beta cell function and HbA1C levels between two patient groups over a one-year follow-up period.
- Trial name
- NCT07574138
- Testing
- Monitor and observe the clinical progression and beta cell function
- Where
- Vietnam
- Volunteers
- 296 people
- Sponsor
- University Medical Center Ho Chi Minh City (UMC)
Diabetes Mellitus
Defining the Molecular and Physiological Mechanisms of Pancreatic Islet Cell Dysfunction Which Lead to Type 2 Diabetes
Defects in insulin secretion are central to the pathogenesis of type 2 diabetes (T2D) but the molecular basis and physiological consequences of those defects are poorly understood, impeding efforts to develop novel therapeutic…
- Trial name
- DIVA-Exeter (NCT02505308)
- Testing
- Glucose-Potentiated Arginine-Induced Insulin Secretion
- Where
- 2 sites in United Kingdom
- Volunteers
- 328 people, healthy volunteers welcome
- Sponsor
- Royal Devon and Exeter NHS Foundation Trust
Type 1 Diabetes Mellitus
Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects
The purpose of this study is to determine whether treatment with multiple injections of GAD-Alum will preserve the body's own (endogenous) insulin production in patients who have been recently diagnosed with type 1 diabetes…
- Trial name
- TN08 (NCT00529399)
- Testing
- GAD-Alum, GAD-Alum and Aluminum hydroxide, Aluminum hydroxide
- Where
- 15 sites in United States, Canada
- Volunteers
- 145 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 1
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.
- Trial name
- NCT07222332
- Testing
- Baricitinib
- Where
- 131 sites in United States, Australia and 18 more
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
A Phase I/II Trial to Preserve Residual Insulin Secretion in Children With Recent Onset Type 1 Diabetes by Giving Verapamil
The objective of this trial is first to evaluate safety and then the effect on preservation of residual beta cell function also clinical efficacy by treatment with Verapamil in children with recent onset Type 1 diabetes.
- Trial name
- VERADIAB-1 (NCT07199946)
- Testing
- Verapamil (Part A)
- Where
- 2 sites in Sweden
- Volunteers
- 36 people
- Sponsor
- Johnny Ludvigsson
Stage 1 Diabetes Mellitus, Type 1
GLP-1 RA for Stage 1 Type 1 Diabetes
This study seeks to evaluate the hormone responses of insulin, c-peptide, glucagon, and incretins to semaglutide, a GLP-1 receptor agonist therapy, in individuals with stage 1 type 1 diabetes.
- Trial name
- NCT07430332
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Diabetes Mellitus, Type 1
Anhydroglucitol in Children With Type 1 Diabetes
The investigators will measure blood levels of 1,5-anhydroglucitol in children with type 1 diabetes and correlate them with parameters related to functional beta-cell mass in diabetic patients.
- Trial name
- NCT05594706
- Testing
- Measurement of blood levels of 1,5-anhydroglucitol
- Where
- Switzerland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva
Type 1 Diabetes
Beta Cell Function in (Pre)Type 1 Diabetes
Increased glycemic variability has been proposed as an independent predictor of hypoglycemia in diabetic patients. Likewise, episodes of dysglycemia have been found to be predictive of diabetes in antibodypositive nondiabetic…
- Trial name
- NCT01402037
- Testing
- Glucose, Continuous glucose monitoring
- Where
- 3 sites in Belgium
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Diabetes Mellitus, Type 1
Prolonged Remission Induced by Phenofibrate in Children Newly Diagnosed With Type 1 Diabetes.
The goal of this clinical trial is to evaluate of the effect of phenofibrate on the functions of beta cells in children with new diagnosis of type 1 diabetes.
- Trial name
- PRIFEN (NCT05909800)
- Testing
- Phenofibrate
- Where
- 2 sites in Poland
- Volunteers
- 102 people
- Sponsor
- Medical University of Warsaw
Type 1 Diabetes Mellitus
Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus
The purpose of this study is to determine whether treatment with CTLA4-Ig (Abatacept) in individuals with new onset T1DM will improve insulin secretion (C-peptide production) compared to placebo.
- Trial name
- TN09 (NCT00505375)
- Testing
- CTLA-4 Ig
- Where
- 13 sites in United States, Canada
- Volunteers
- 112 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)